Answers are grounded in this paper and cite their sources.
Volatile terpenes and terpenoids in exhaled breath have emerged as intriguing candidates for noninvasive biomarker development, yet their clinical relevance remains debated due to their assumed exogenous origin. This Perspective seeks to review the key literature on exhaled terpenes and highlight their potential as xenobiotic biomarkers to monitor a wide range of medical conditions. Through a fusion of breathomics, pharmacokinetics, and an understanding of cytochrome P450 induced metabolism, we argue that terpenes could report on disease-specific enzymatic activities and offer advantages over traditional endogenous VOCs, particularly toward early-stage detection. We propose strategies for identifying novel terpene substrates, biomarker validation, and integration with nanosensor platforms for point-of-care detection. If realized, xenobiotic terpene/terpenoid biomarkers could represent a paradigm shift in breath-based diagnostics by demonstrating that naturally occurring compounds introduced exogenously can function as intentional probes for noninvasive health monitoring.
No takes yet. Share an insight, caveat, or question.
Woollam et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: